Despite the introduction of new molecular subdivisions (CMS1–4), advanced CRC is treated systemically with chemotherapy (e.g., FOLFOX) supplemented with anti-EGFR and anti-VEGF targeted therapy7. This evidence concerns the gene EGFR and colorectal carcinoma.